DK0456724T3 - Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi - Google Patents

Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi

Info

Publication number
DK0456724T3
DK0456724T3 DK90902952.2T DK90902952T DK0456724T3 DK 0456724 T3 DK0456724 T3 DK 0456724T3 DK 90902952 T DK90902952 T DK 90902952T DK 0456724 T3 DK0456724 T3 DK 0456724T3
Authority
DK
Denmark
Prior art keywords
composition
benign prostatic
prostatic hypertrophy
treating benign
preferably comprises
Prior art date
Application number
DK90902952.2T
Other languages
English (en)
Inventor
Muharrem Gokcen
Terry J Guy
Original Assignee
Immunolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunolytics Inc filed Critical Immunolytics Inc
Application granted granted Critical
Publication of DK0456724T3 publication Critical patent/DK0456724T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90902952.2T 1989-01-27 1990-01-19 Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi DK0456724T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30380989A 1989-01-27 1989-01-27
US42996689A 1989-10-31 1989-10-31

Publications (1)

Publication Number Publication Date
DK0456724T3 true DK0456724T3 (da) 1995-10-02

Family

ID=26973659

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90902952.2T DK0456724T3 (da) 1989-01-27 1990-01-19 Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi

Country Status (10)

Country Link
US (1) US6296847B1 (da)
EP (1) EP0456724B1 (da)
JP (1) JP3054190B2 (da)
AT (1) ATE121946T1 (da)
AU (1) AU5045690A (da)
DE (1) DE69019141T2 (da)
DK (1) DK0456724T3 (da)
ES (1) ES2072424T3 (da)
HK (1) HK1003981A1 (da)
WO (1) WO1990008555A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305460C2 (de) * 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
WO2001021574A1 (en) * 1999-09-24 2001-03-29 Johns Hopkins University Systems and methods for opening obstructed biological conduits
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6678391B2 (en) * 2000-04-18 2004-01-13 Matsushita Electric Industrial Co., Ltd. Organism-specimen morphological-change detecting apparatus, and organism-specimen morphological-change detecting method
WO2002074329A1 (en) * 2001-03-19 2002-09-26 Ribeiro Santana Cristiano Albe Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process
AU2003212195A1 (en) * 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Protease screening and novel use of proteases
EP1521523A4 (en) * 2002-05-20 2006-04-19 Univ Texas METHODS AND COMPOSITIONS FOR DELIVERING NUCLEIC ACID ENZYMES AND MOLECULES IN BRAIN, BONE, AND OTHER FABRICS
AU2002333006A1 (en) * 2002-09-19 2004-04-08 Gilberto De Nucci Pharmaceutical composition comprising carriers for products
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
ES2420430T3 (es) 2005-03-03 2013-08-23 Allergan, Inc. Sistema libre de productos de origen animal y procedimiento de purificación de una toxina botulínica
KR101447184B1 (ko) * 2006-11-10 2014-10-08 엘아이지에이디피 주식회사 게이트슬릿 개폐장치가 구비된 공정챔버
CA2678038C (en) * 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
AT506095A1 (de) * 2007-12-03 2009-06-15 Volopharm Gmbh Verwendung von proteasen
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2672958A1 (en) * 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP6049714B2 (ja) 2011-07-20 2016-12-21 メディウンド リミテッド 結合組織疾患の治療のためのブロメライン由来タンパク質分解抽出物
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
BR112015002768B1 (pt) 2012-08-10 2022-05-03 Osio Corporation d/b/a Yolia Health Método para determinar um ajuste de uma lente de contato em um olho e lente de contato
US10835538B2 (en) * 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3792161A (en) 1970-05-18 1974-02-12 Research Corp Burn ointment comprising silver sulfadiazine and collagenase
US3678158A (en) 1971-05-11 1972-07-18 Worthington Bio Chem Corp Treatment of herniated intervertebral discs of mammals
US4276284A (en) 1971-07-26 1981-06-30 Brown Stuart I Prevention of collagenase induced disease by treatment with collagenase inhibitors
US3977408A (en) 1974-11-01 1976-08-31 Mackew Allan H Prosthetic catheter
US4005194A (en) 1975-06-23 1977-01-25 Abbott Laboratories Treatment of prostatic hyperplasia
US4317818A (en) 1976-05-10 1982-03-02 Richardson-Merrell Inc. Method of treating prostatic carcinoma
DE2655801C2 (de) 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
US4174389A (en) 1977-05-13 1979-11-13 Cope Louise A Ophthalmic use of collagenase
CH624011A5 (da) 1977-08-05 1981-07-15 Battelle Memorial Institute
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4329430A (en) * 1979-06-04 1982-05-11 Klein Gerold K V Enzyme mixture
US4317817A (en) 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4276281A (en) 1980-09-04 1981-06-30 Crikelair George F Burn treatment
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS58189122A (ja) 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd 高脂血症予防治療剤
JPS5951221A (ja) 1982-09-17 1984-03-24 Eisai Co Ltd 変形性関節症治療剤
IT1189379B (it) * 1982-10-08 1988-02-04 Serono Ist Farm Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4678668A (en) * 1985-10-28 1987-07-07 Md Associates Method of reducing soft tissue swelling and pain
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
HK1003981A1 (en) 1998-11-13
DE69019141D1 (de) 1995-06-08
ATE121946T1 (de) 1995-05-15
DE69019141T2 (de) 1996-01-18
EP0456724B1 (en) 1995-05-03
JPH04503071A (ja) 1992-06-04
WO1990008555A1 (en) 1990-08-09
EP0456724A1 (en) 1991-11-21
US6296847B1 (en) 2001-10-02
AU5045690A (en) 1990-08-24
JP3054190B2 (ja) 2000-06-19
ES2072424T3 (es) 1995-07-16

Similar Documents

Publication Publication Date Title
DK0456724T3 (da) Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi
ATE373483T1 (de) Zusammensetzung zur behandlung von prostatakrebs
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
FI964033A (fi) Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja
CO5011115A1 (es) Compuestos y metodos quimioquina
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DK1140078T3 (da) Vaskulærskadende benzimidazolmidler
ATE350044T1 (de) Thrombopoietinmimetika
DE60025632D1 (de) Thrombopoietin-mimetika
DK0510073T3 (da) Fremgangsmåde til forøgelse af fertiliteten hos hankønsvæsener
BR9811099A (pt) Inibidores de urocinase
SE0001914D0 (sv) Förbättring av Peyronies sjukdom
DK1053239T3 (da) Gluccocorticoid-selektive, anti-inflammatoriske midler
DE60031714D1 (de) Thrombopoietin-mimetika
ATE224386T1 (de) Neue in 6-position substituierte phenanthridine
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
ES2186308T3 (es) Procedimento de revestimiento metalico de fibras por via liquida.
DK180682A (da) Fremgangsmaade til fremstilling af et fibrinolytisk aktivt kar-princip og herved vundet enzymatisk produkt
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
EP0817645A4 (en) METHOD FOR TREATING BENIGN PROSTATIC HYPERTROPHY
BR9804769A (pt) Processo para tratar ou prevenir infecção por pestivìrus em um hospedeiro mamìfero tendo ou sendo suscetìvel a referida infecção,e , para tratar c~elulas de mamìferos em cultura, e, em mamìferos biológicos
NO983103L (no) Nye monofunksjonelle EDTA-, DTPA- og TTHA-derivater og deres anvendelse i medisinsk diagnostikk og terapi
AU4132397A (en) Therapeutic formulations containing venom or venom anti-serum either lone or in combination for the therapeutic prophylaxis and therapy of neoplasms